Redx Pharma has quickly established itself as one of the largest biotechnology companies in Europe, focused on the development of a wide range of early stage, proprietary small molecule therapeutics to address high unmet medical needs in cancer and infectious disease.

Find out more

Latest News

Redx Pharma appoints new chairman
1 September 2014

Redx Pharma has today appointed Dr Frank Armstrong as its non-executive chairman.

Frank, 57, brings a wealth of industry knowledge and highly relevant experience of oncology and anti-infectives, two of the areas of early stage drug research that have driven expansion at the company, which operates from bases in Liverpool and Alderley Park, Cheshire.

Dr Peter Jackson, co-founder and director at Redx, said: We are delighted to welcome Frank to our board. His pharma business experience and clinical insight will make a valuable contribution to our plans for further growth and he is extremely well networked internationally. His skills and instincts are closely aligned to the breadth of our programmes in oncology and anti-infectives, and our early-stage partnering business model.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

 176 employees already

Updated 31/07/14

We Sponsored

BioInfect 2013, a major one-day conference looking at the critical issues relating to the development of new anti-infectives and the problem of drug resistance.

Watch the highlights

Read more about our involvement

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details

Finding new intellectual property that supports development of novel agrochemicals with shorter, less costly development cycles.

View details